{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:30:43Z","timestamp":1790346643084,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["138204"],"award-info":[{"award-number":["138204"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13643-017-0492-9","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T13:20:47Z","timestamp":1495200047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Polypharmacy in multimorbid older adults: protocol for a systematic review"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-7883","authenticated-orcid":false,"given":"Caroline","family":"Sirois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Gu\u00e9nette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edeltraut","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"\u00c9mond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"492_CR1","volume-title":"Drug use among seniors on public drug programs in Canada, 2012; revised 2014","author":"Canadian Institute for Health Information","year":"2014","unstructured":"Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada, 2012; revised 2014. Ottawa: CIHI; 2014."},{"key":"492_CR2","doi-asserted-by":"publisher","unstructured":"Moriarty F, Hardy C, Bennett K, Smith S, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5(9):e008656. doi: 10.1136\/bmjopen-2015-008656 .","DOI":"10.1136\/bmjopen-2015-008656"},{"key":"492_CR3","first-page":"CD008165","volume":"5","author":"SM Patterson","year":"2012","unstructured":"Patterson SM, Hughes C, Kerse N, Cardwell CR, Bradley MC. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2012;5:CD008165.","journal-title":"Cochrane Database Syst Rev"},{"key":"492_CR4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jclinepi.2012.02.018","volume":"65","author":"D Gnjidic","year":"2012","unstructured":"Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989\u201395.","journal-title":"J Clin Epidemiol"},{"key":"492_CR5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1532-5415.2006.00889.x","volume":"54","author":"MA Steinman","year":"2006","unstructured":"Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516\u201323.","journal-title":"J Am Geriatr Soc"},{"key":"492_CR6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0735-6757(96)90147-3","volume":"14","author":"RM Goldberg","year":"1996","unstructured":"Goldberg RM, Mabee J, Chan L, Wong S. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447\u201350.","journal-title":"Am J Emerg Med"},{"key":"492_CR7","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","volume":"30","author":"K Johnell","year":"2007","unstructured":"Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911\u20138.","journal-title":"Drug Saf"},{"key":"492_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.diabres.2009.10.019","volume":"87","author":"GE Caughey","year":"2010","unstructured":"Caughey GE, Roughead E, Vitry A, McDermott RA, Shakib S, Gilbert A. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Pract. 2010;87:385\u201393.","journal-title":"Diabetes Res Clin Pract"},{"key":"492_CR9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/archinte.164.18.1957","volume":"164","author":"JH Gurwitz","year":"2004","unstructured":"Gurwitz JH. Polypharmacy: a new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004;164:1957\u20139.","journal-title":"Arch Intern Med"},{"key":"492_CR10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.amjopharm.2007.12.009","volume":"5","author":"MA Steinman","year":"2007","unstructured":"Steinman MA. Polypharmacy and the balance of medication benefits and risks. Am J Geriatr Pharmacother. 2007;5:314\u20136.","journal-title":"Am J Geriatr Pharmacother"},{"key":"492_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cger.2012.01.001","volume":"28","author":"B Hovstadius","year":"2012","unstructured":"Hovstadius B, Petersson G. Factors leading to excessive polypharmacy. Clin Geriatr Med. 2012;28:159\u201372.","journal-title":"Clin Geriatr Med"},{"key":"492_CR12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","volume":"5","author":"ER Hajjar","year":"2007","unstructured":"Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345\u201351.","journal-title":"Am J Geriatr Pharmacother"},{"key":"492_CR13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1041-2972.2005.0020.x","volume":"17","author":"MM Fulton","year":"2005","unstructured":"Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract. 2005;17:123\u201332.","journal-title":"J Am Acad Nurse Pract"},{"key":"492_CR14","first-page":"624","volume":"63","author":"SR Sabzwari","year":"2013","unstructured":"Sabzwari SR, Qidwai W, Bhanji S. Polypharmacy in elderly: a cautious trail to tread. J Pak Med Assoc. 2013;63:624\u20137.","journal-title":"J Pak Med Assoc"},{"key":"492_CR15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cger.2007.01.002","volume":"23","author":"BD Hayes","year":"2007","unstructured":"Hayes BD, Klein-Schwartz W, Barrueto Jr F. Polypharmacy and the geriatric patient. Clin Geriatr Med. 2007;23:371\u201390. vii.","journal-title":"Clin Geriatr Med"},{"key":"492_CR16","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0895-4356(02)00411-0","volume":"55","author":"T Linjakumpu","year":"2002","unstructured":"Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809\u201317.","journal-title":"J Clin Epidemiol"},{"key":"492_CR17","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1345\/aph.10351","volume":"35","author":"T Jorgensen","year":"2001","unstructured":"Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35:1004\u20139.","journal-title":"Ann Pharmacother"},{"key":"492_CR18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s002280050445","volume":"54","author":"L Bjerrum","year":"1998","unstructured":"Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol. 1998;54:197\u2013202.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"492_CR19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.24095\/hpcdp.34.4.06","volume":"34","author":"C Blais","year":"2014","unstructured":"Blais C, Jean S, Sirois C, Rochette L, Plance C, Larocque I, et al. Quebec Integrated Chronic Disease Surveillance System (QICDSS), an innovative approach. Chronic Dis Inj Can. 2014;34(4):226\u201335.","journal-title":"Chronic Dis Inj Can"},{"key":"492_CR20","unstructured":"SIGN 50: a guideline developers' handbook [Internet]. Edinburgh: The Network; 2008. Annex C. Methodology checklist 2: randomised controlled trials; p.52. http:\/\/www.sign.ac.uk\/methodology\/checklists.html . Accessed 6 June 2008."},{"key":"492_CR21","unstructured":"Methodology checklist 3: cohort studies. In: SIGN 50: a guideline developers' handbook. Edinburgh: The Network; 2004. Chapter Annex C at http:\/\/www.sign.ac.uk\/methodology\/checklists.html )"},{"key":"492_CR22","unstructured":"Methodology checklist 4: case\u2013control studies [Internet]. In: SIGN 50: a guideline developers' handbook. Edinburgh: The Network; 2004. Chapter Annex C. at http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/50\/checklist4.html )"},{"key":"492_CR23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jclinepi.2012.11.009","volume":"66","author":"C Glenton","year":"2013","unstructured":"Glenton C, Lewin S, Mayhew A, Scheel I, Odgaard-Jensen J. Nonrandomized studies are not always found even when selection criteria for health systems intervention reviews include them: a methodological study. J Clin Epidemiol. 2013;66:367\u201370.","journal-title":"J Clin Epidemiol"},{"key":"492_CR24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.healthpol.2011.12.007","volume":"104","author":"PC Rockers","year":"2012","unstructured":"Rockers PC, Feigl AB, Rottingen JA, et al. Study-design selection criteria in systematic reviews of effectiveness of health systems interventions and reforms: a meta-review. Health Policy. 2012;104:206\u201314.","journal-title":"Health Policy"},{"key":"492_CR25","doi-asserted-by":"crossref","first-page":"f7033","DOI":"10.1136\/bmj.f7033","volume":"347","author":"J Wise","year":"2013","unstructured":"Wise J. Polypharmacy: a necessary evil. BMJ. 2013;347:f7033.","journal-title":"BMJ"},{"key":"492_CR26","unstructured":"Polypharmacy and medicines optimisation: making it safe and sound. London, 2013. 2013. at http:\/\/www.kingsfund.org.uk\/sites\/files\/kf\/field\/field_publication_file\/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf )"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-017-0492-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T19:01:16Z","timestamp":1659034876000},"score":1,"resource":{"primary":{"URL":"http:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-017-0492-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["492"],"URL":"https:\/\/doi.org\/10.1186\/s13643-017-0492-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"article-number":"104"}}